Biogen Inc (BIIB)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	2,375,000	1,699,200	1,908,900	1,074,400	1,049,900	2,287,900	2,617,800	2,898,200	3,419,300	3,675,600	2,646,600	1,749,300	2,261,400	1,541,800	1,742,000	1,217,500	1,331,200	2,224,800	2,384,900	2,591,300
Short-term investments	US$ in thousands	179,700	304,700	302,700	329,500	416,800	413,600	4,177,500	2,821,200	2,264,600	2,131,500	2,936,900	2,862,700	2,589,600	2,579,500	1,308,800	1,320,000	1,278,900	1,355,000	1,942,700	1,269,100
Total current liabilities	US$ in thousands	5,528,800	5,425,000	3,108,200	3,222,800	3,434,300	5,022,300	3,186,500	3,014,900	3,272,800	3,926,400	5,018,000	3,946,600	4,298,200	4,211,600	3,347,200	3,165,800	3,742,200	3,804,000	3,447,100	4,638,600
Cash ratio		0.46	0.37	0.71	0.44	0.43	0.54	2.13	1.90	1.74	1.48	1.11	1.17	1.13	0.98	0.91	0.80	0.70	0.94	1.26	0.83

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,375,000K + $179,700K) ÷ $5,528,800K
= 0.46

The cash ratio of Biogen Inc has shown varying trends over the period from March 31, 2020, to December 31, 2024. The cash ratio started at 0.83 on March 31, 2020, reached a peak of 2.13 on June 30, 2023, and fluctuated afterwards. The cash ratio measures the company's ability to cover its short-term liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger liquidity position, as the company has more cash on hand relative to its short-term obligations. Biogen's cash ratio improved significantly from March 31, 2020, to June 30, 2023, suggesting more liquidity and better ability to meet short-term obligations during that period. However, there were fluctuations in the cash ratio in the following periods, indicating potential changes in the company's cash position and liquidity. It is important for investors and analysts to closely monitor Biogen's cash ratio to assess its short-term liquidity health.